Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024
Curis (NASDAQ: CRIS) has announced it will release its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m. ET. The biotechnology company, which focuses on developing emavusertib (CA-4948), an oral IRAK4 inhibitor, will host a conference call and webcast at 8:30 a.m. ET on the same day. Participants can join via phone or access the live audio webcast through the investor section of the Curis website.
Curis (NASDAQ: CRIS) ha annunciato che pubblicherà i suoi risultati finanziari e operativi del terzo trimestre 2024 giovedì 14 novembre 2024, alle 8:00 ora orientale. L'azienda biotecnologica, che si concentra sullo sviluppo di emavusertib (CA-4948), un inibitore orale di IRAK4, ospiterà una teleconferenza e un webcast alle 8:30 ora orientale dello stesso giorno. I partecipanti possono unirsi tramite telefono o accedere al webcast audio in diretta attraverso la sezione investitori del sito web di Curis.
Curis (NASDAQ: CRIS) ha anunciado que publicará sus resultados financieros y operativos del tercer trimestre de 2024 el jueves 14 de noviembre de 2024, a las 8:00 a.m. ET. La compañía de biotecnología, que se enfoca en el desarrollo de emavusertib (CA-4948), un inhibidor oral de IRAK4, llevará a cabo una llamada de conferencia y un webcast a las 8:30 a.m. ET el mismo día. Los participantes pueden unirse por teléfono o acceder al webcast de audio en vivo a través de la sección de inversores del sitio web de Curis.
Curis (NASDAQ: CRIS)는 2024년 11월 14일 목요일 오전 8시(ET)에 2024년 3분기 재무 및 운영 결과를 발표할 것이라고 발표했습니다. IRAK4의 경구용 억제제인 emavusertib (CA-4948) 개발에 중점을 둔 생명공학 회사는 같은 날 오전 8시 30분(ET)에 전화 회의 및 웹캐스트를 개최합니다. 참가자는 전화로 참여하거나 Curis 웹사이트의 투자자 섹션을 통해 실시간 오디오 웹캐스트에 접속할 수 있습니다.
Curis (NASDAQ: CRIS) a annoncé qu'il publiera ses résultats financiers et opérationnels du troisième trimestre 2024 le jeudi 14 novembre 2024 à 8h00, heure de l'Est. La société de biotechnologie, qui se concentre sur le développement de l'emavusertib (CA-4948), un inhibiteur oral de l'IRAK4, organisera une conférence téléphonique et un webcast le même jour à 8h30, heure de l'Est. Les participants peuvent se joindre par téléphone ou accéder au webcast audio en direct via la section investisseurs du site Web de Curis.
Curis (NASDAQ: CRIS) hat angekündigt, dass am Donnerstag, dem 14. November 2024, um 8:00 Uhr ET die Finanz- und Betriebsergebnisse für das dritte Quartal 2024 veröffentlicht werden. Das Biotechnologieunternehmen, das sich auf die Entwicklung von emavusertib (CA-4948), einem oralen IRAK4-Inhibitor, konzentriert, wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten. Teilnehmer können sich telefonisch einwählen oder über die Investoren-Seite der Curis-Website auf den Live-Audio-Webcast zugreifen.
- None.
- None.
Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can be accessed here from the investor section of the Curis website. A replay of the conference call will be available at www.curis.com.
About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS) with either a FLT3 mutation or a splicing factor mutation (U2AF1 or SF3B2), and as a frontline combination therapy with azacitidine and venetoclax in patents with AML. Emavusertib has received Orphan Drug Designation from the
View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-report-third-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-november-14-2024-302298003.html
SOURCE Curis, Inc.
FAQ
When will Curis (CRIS) report Q3 2024 earnings?
How can investors access Curis (CRIS) Q3 2024 earnings call?
What is the main product Curis (CRIS) is developing?
